{"transactions":[{"id":959955,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-12-23T22:12:03.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":5502402,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The securities were issued to Sermonix Pharmaceuticals, Inc. (\"Sermonix\") in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants will become exercisable upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval. The Pre-Funded Warrants do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The securities were issued to Sermonix Pharmaceuticals, Inc. (\"Sermonix\") in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants will become exercisable upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval. The Pre-Funded Warrants do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The terms of the Pre-Funded Warrants provide that such warrants may not be exercised if, after such exercise, Sermonix, together with its Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 4.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the \"Sermonix Beneficial Ownership Limitation\"). As of the date hereof, the Sermonix Beneficial Ownership Limitation does not permit Sermonix to exercise any of its Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The securities were issued to Sermonix Pharmaceuticals, Inc. (\"Sermonix\") in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants will become exercisable upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval. The Pre-Funded Warrants do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The securities are directly held by Sermonix. An affiliate of the Advisor currently holds approximately 29% of the outstanding capital stock of Sermonix (excluding securities convertible into shares of Sermonix capital stock). Pursuant to General Instruction 4.b.(iv) of Form 4, the Reporting Persons with this filing have reported the entire amount of Sermonix's interest in the securities, rather than the Reporting Person's proportionate interest in the securities held by Sermonix."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":5502402,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":5502402},"source":{"system":"sec-edgar","filing":"0001012975-25-000979","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000101297525000979/form4.xml","form_type":"4"}},{"id":959954,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (right to buy)","published_at":"2025-12-23T22:12:03.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":1181101,"price":6.35,"value":7499991.35,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the \"Series B Expiration Date\") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the \"Beneficial Ownership Limitation\"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the \"Series B Expiration Date\") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Xontogeny Venture Fund II, LP (\"PXV II\"). Perceptive Venture Advisors, LLC (the \"Venture Advisor\") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC (\"PXV GP\") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":1181101,"derivative":{"exercise_price":7.62,"underlying":"Common Stock","underlying_shares":1181101},"source":{"system":"sec-edgar","filing":"0001012975-25-000979","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000101297525000979/form4.xml","form_type":"4"}},{"id":959953,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant (right to buy)","published_at":"2025-12-23T22:12:03.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":1279526,"price":6.35,"value":8124990.1,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the \"Series A Expiration Date\") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the \"Beneficial Ownership Limitation\"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the \"Series A Expiration Date\") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Xontogeny Venture Fund II, LP (\"PXV II\"). Perceptive Venture Advisors, LLC (the \"Venture Advisor\") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC (\"PXV GP\") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":1279526,"derivative":{"exercise_price":6.35,"underlying":"Common Stock","underlying_shares":1279526},"source":{"system":"sec-edgar","filing":"0001012975-25-000979","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000101297525000979/form4.xml","form_type":"4"}},{"id":959952,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-12-23T22:12:03.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":457645,"price":6.349,"value":2905588.105,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the \"Beneficial Ownership Limitation\"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Xontogeny Venture Fund II, LP (\"PXV II\"). Perceptive Venture Advisors, LLC (the \"Venture Advisor\") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC (\"PXV GP\") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":457645,"derivative":{"exercise_price":0.001,"exercise_date":"2025-12-23","underlying":"Common Stock","underlying_shares":457645},"source":{"system":"sec-edgar","filing":"0001012975-25-000979","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000101297525000979/form4.xml","form_type":"4"}},{"id":959951,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (right to buy)","published_at":"2025-12-23T22:12:03.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":3543307,"price":6.35,"value":22499999.45,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the \"Series B Expiration Date\") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the \"Beneficial Ownership Limitation\"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the \"Series B Expiration Date\") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":3543307,"derivative":{"exercise_price":7.62,"underlying":"Common Stock","underlying_shares":3543307},"source":{"system":"sec-edgar","filing":"0001012975-25-000979","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000101297525000979/form4.xml","form_type":"4"}},{"id":959950,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant (right to buy)","published_at":"2025-12-23T22:12:03.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":3838583,"price":6.35,"value":24375002.05,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the \"Series A Expiration Date\") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the \"Beneficial Ownership Limitation\"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the \"Series A Expiration Date\") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":3838583,"derivative":{"exercise_price":6.35,"underlying":"Common Stock","underlying_shares":3838583},"source":{"system":"sec-edgar","filing":"0001012975-25-000979","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000101297525000979/form4.xml","form_type":"4"}},{"id":959949,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-12-23T22:12:03.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":1372935,"price":6.349,"value":8716764.315,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the \"Beneficial Ownership Limitation\"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":1372935,"derivative":{"exercise_price":0.001,"exercise_date":"2025-12-23","underlying":"Common Stock","underlying_shares":1372935},"source":{"system":"sec-edgar","filing":"0001012975-25-000979","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000101297525000979/form4.xml","form_type":"4"}},{"id":959948,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T22:12:03.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":329756,"price":6.35,"value":2093950.6,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Xontogeny Venture Fund II, LP (\"PXV II\"). Perceptive Venture Advisors, LLC (the \"Venture Advisor\") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC (\"PXV GP\") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":329756,"source":{"system":"sec-edgar","filing":"0001012975-25-000979","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000101297525000979/form4.xml","form_type":"4"}},{"id":959947,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T22:12:03.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":989270,"price":6.35,"value":6281864.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":1529566,"source":{"system":"sec-edgar","filing":"0001012975-25-000979","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000101297525000979/form4.xml","form_type":"4"}},{"id":1742594,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":3,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":4,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-11-14T21:32:43.000Z","date":"2023-11-14","kind":"exercise","planned":false,"acquired":false,"shares":2579502,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. (\"PXV II\"). Perceptive Venture Advisors, LLC (the \"Venture Advisor\") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the \"Advisor\"), and Perceptive Xontogeny Venture II GP, LLC (\"PXV GP\") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2579502},"source":{"system":"sec-edgar","filing":"0001062993-23-020811","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323020811/form4.xml","form_type":"4"}},{"id":1742593,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":3,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":4,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2023-11-14T21:32:43.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":333333,"price":15,"value":4999995.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  The Advisor serves as the investment manager of Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":333333,"source":{"system":"sec-edgar","filing":"0001062993-23-020811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323020811/form4.xml","form_type":"4"}},{"id":1742592,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":3,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":4,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2023-11-14T21:32:43.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":333333,"price":15,"value":4999995.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. (\"PXV II\"). Perceptive Venture Advisors, LLC (the \"Venture Advisor\") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the \"Advisor\"), and Perceptive Xontogeny Venture II GP, LLC (\"PXV GP\") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":2912835,"source":{"system":"sec-edgar","filing":"0001062993-23-020811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323020811/form4.xml","form_type":"4"}},{"id":1742591,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":3,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":4,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2023-11-14T21:32:43.000Z","date":"2023-11-14","kind":"exercise","planned":false,"acquired":true,"shares":2579502,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. (\"PXV II\"). Perceptive Venture Advisors, LLC (the \"Venture Advisor\") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the \"Advisor\"), and Perceptive Xontogeny Venture II GP, LLC (\"PXV GP\") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":2579502,"source":{"system":"sec-edgar","filing":"0001062993-23-020811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323020811/form4.xml","form_type":"4"}},{"id":2056675,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82935,"kind":"person","name":"Perceptive Xontogeny Venture Fund, LP","position":3,"cik":"0001757940","reported_name":"Perceptive Xontogeny Venture Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":5,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant","published_at":"2023-01-11T23:45:00.000Z","date":"2023-01-10","kind":"purchase","acquired":true,"shares":3636363,"price":0.54,"value":1963636.02,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any \"group\" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any \"group\" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by PX Venture (A), LLC (\"PX Venture\").  The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":3636363,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":3636363},"source":{"system":"sec-edgar","filing":"0001062993-23-000853","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323000853/form4.xml","form_type":"4"}},{"id":2056674,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82935,"kind":"person","name":"Perceptive Xontogeny Venture Fund, LP","position":3,"cik":"0001757940","reported_name":"Perceptive Xontogeny Venture Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":70910,"kind":"person","name":"Perceptive Xontogeny Venture Fund II, LP","position":4,"cik":"0001851820","reported_name":"Perceptive Xontogeny Venture Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":5,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant","published_at":"2023-01-11T23:45:00.000Z","date":"2023-01-10","kind":"purchase","acquired":true,"shares":27272727,"price":0.54,"value":14727272.58,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any \"group\" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any \"group\" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. (\"PXV II\").  The Advisor serves as the investment manager of PXV II, and Perceptive Xontogeny Venture II GP, LLC (\"PXV GP\") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":27272727,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":27272727},"source":{"system":"sec-edgar","filing":"0001062993-23-000853","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323000853/form4.xml","form_type":"4"}}]}